Indication
Beta-Thalassemia
8 clinical trials
8 products
Product
AND017Clinical trial
A Study of Safety and Efficiency of AND017 in Patients With Transfusion Dependent and Non-transfusion Dependent β-thalassemiaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)Status: Active (not recruiting), Estimated PCD: 2024-04-01
Product
MitapivatClinical trial
A Phase I/II Clinical Study Evaluating the Safety and Efficacy of KL003 Cell Injection in Transfusion-dependent β-thalassemiaStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Product
KL003 Cell InjectionClinical trial
Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients: A Pharmacodynamics and Pharmacogenetics AnalysisStatus: Completed, Estimated PCD: 2023-07-20
Product
ThalidomideClinical trial
Evaluation of the Safety and Efficacy of KL003 Gene Therapy in Patients With Transfusion-dependent β-thalassemia With No Conditioning RegimenStatus: Recruiting, Estimated PCD: 2025-12-31
Product
KL003 cell injectionClinical trial
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.Status: Recruiting, Estimated PCD: 2025-08-20
Clinical trial
Growth and Development, Health-related Quality of Life of Children With Transfusion-dependent Beta-thalassemia After Gene TherapyStatus: Recruiting, Estimated PCD: 2028-12-31
Product
Gene therapyClinical trial
An Open Label Study Evaluating the Safety and Efficacy of Gene Therapy for Transfusion-dependent β-Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a LentiRed Lentiviral Vector (GMCN-508B Drug Product, Also Called LentiRed)Status: Recruiting, Estimated PCD: 2028-04-01
Product
GMCN-508B